Patient-reported outcomes in asian patients with chronic hepatitis c treated with ledipasvir and sofosbuvir

Medicine (United States)

Volumn 95, Issue 9, 2016, Pages

  Younossi, Zobair M ^a,b   Stepanova, Maria ^c   Chan, Henry L Y ^d   Lee, Mei H ^e   Yu, Ming Lung ^f   Dan, Yock Y ^g   Choi, Moon S ^h   Henry, Linda ^c  

^a Department of Medicine   (United States)

^b Betty and Guy Beatty Center for Integrated Research   (United States)

^c Center for Outcomes Research in Liver Diseases   (United States)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^e NATIONAL YANG MING UNIVERSITY   (Taiwan)

^f KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^g NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^h Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

LEDIPASVIR; SOFOSBUVIR; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; FLUORENE DERIVATIVE;

ADULT; AGE; ANTIVIRAL THERAPY; ANXIETY DISORDER; ARTICLE; ASIAN; BODY MASS; CHRONIC HEPATITIS C; CONTROLLED STUDY; DEPRESSION; FEMALE; HUMAN; HYPERGLYCEMIA; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RETROSPECTIVE STUDY; SHORT FORM 36; SLEEP DISORDER; TREATMENT OUTCOME; ASIA; COMBINATION DRUG THERAPY; DRUG EFFECTS; HEPACIVIRUS; HEPATITIS C, CHRONIC; OUTCOME ASSESSMENT; PROCEDURES; PSYCHOLOGY; QUALITY OF LIFE; QUESTIONNAIRE; VIROLOGY;

ANTIVIRAL AGENTS; ASIA; BENZIMIDAZOLES; DRUG THERAPY, COMBINATION; FEMALE; FLUORENES; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; PATIENT OUTCOME ASSESSMENT; QUALITY OF LIFE; SOFOSBUVIR; SURVEYS AND QUESTIONNAIRES;

EID: 84962509042     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000002702     Document Type: Article

References (37)

1. Sievert W, Altraif I, Razavi HA, et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int. 2011;31(Suppl 2):61-80. doi: 10.1111/j.1478-3231.2011.-02540.x.
2. Yoshii E, Shinzawa H, Saito T, et al. Molecular epidemiology of hepatitis C virus infection in an area endemic for communityacquired acute hepatitis C. Tohoku J Exp Med. 1999;188:311-316.
3. Spradling PR, Rupp L, Moorman AC, et al. Hepatitis B and C virus infection among 1.2 million persons with access to care: factors associated with testing and infection prevalence. Clin Infect Dis. 2012;55:1047-1055.
4. Ditah I, Ditah F, Devaki P, et al. The changing epidemiology of hepatitis C virus infection in the United States: National Health and Nutrition Examination Survey 2001 through 2010. J Hepatol. 2014;60:691-698. doi: 10.1016/j.jhep.2013.11.014. Epub 2013 Nov 27.
5. Denniston MM, Jiles RB, Drobeniuc J, et al. Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010. Ann Intern Med. 2014;160:293-300. doi: 10.7326/M13-1133.
6. Wasitthankasem R, Vongpunsawad S, Siripon N, et al. Poovorawan Y1. Genotypic distribution of hepatitis C virus in Thailand and southeast Asia. PLoS One. 2015;10:e0126764. doi: 10.1371/journal. pone.0126764.
7. eCollection 2015.
8. Manos MM, Shvachko VA, Murphy RC, et al. Distribution of hepatitis C virus genotypes in a diverse US integrated health care population. J Med Virol. 2012;84:1744-1750. doi: 10.1002/jmv.23399.
9. Younossi ZM, Jiang Y, Smith NJ, et al. Ledipasvir/sofosbuvir regimens for chronic hepatitis C infection: Insights from a work productivity economic model from the United States. Hepatology. 2015;61:1471-1478.
10. Rein DB, Wittenborn JS, Smith BD, et al. The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus. Clin Infect Dis. 2015;61:157-168.
11. Younossi ZM, Stepanova M, Marcellin P, et al. Hun. Treatment with ledipasvir and sofosbuvir improves patient-reported outcomes: Results from the ION-1,-2, and-3 clinical trials. Hepatology. 2015;61:1798-1808.
12. Younossi ZM, Stepanova M, Zeuzem S, et al. Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: The VALENCE study. J Hepatol. 2014;61:228-234. doi: 10.1016/j.jhep.2014.04.003. Epub 2014 Apr 5.
13. Younossi ZM, Stepanova M, Nader F, et al. Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens. Hepatology. 2014;59:2161-2169. doi: 10.1002/hep.27161. Epub 2014 Apr 30.
14. Aggarwal J, Vera-Llonch M, Donepudi M, et al. Work productivity among treatment-naïve patients with genotype 1 chronic hepatitis C infection receiving telaprevir combination treatment. J Viral Hepat. 2015;22:8-17. doi: 10.1111/jvh.12227. Epub 2014 Feb 16.
15. Younossi ZM, Stepanova M, Henry L, et al. Effects of sofosbuvirbased treatment, with and without interferon, on outcome and productivity of patients with chronic hepatitis C. Clin Gastroenterol Hepatol. 2014;12:1349-59e13. doi: 10.1016/j.cgh.2013.11.032.
16. Younossi Z, Henry L. Systematic review: patient-reported outcomes in chronic hepatitis C-The impact of liver disease and new treatment regimens. Aliment Pharmacol Ther. 2015;41:497-520. doi: 10.1111/apt.13090. Epub 2015 Jan 23.
17. Younossi ZM, Stepanova M, Sulkowski M, et al. Sofosbuvir and ribavirin for treatment of chronic hepatitis C in patients coinfected with hepatitis C virus and HIV: The impact on patient-reported outcomes. J Infect Dis. 2015;212:367-377.
18. Younossi Z, Henry L. The impact of the new antiviral regimens on patient reported outcomes and health economics of patients with chronic hepatitis C. Dig Liver Dis. 2014;46(Suppl 5):S186-S196. doi: 10.1016/j.dld.2014.09.025. Epub 2014 Nov 10.
19. Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368:1867-1877.
20. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368:1878-1887.
21. Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370: 1889-1898.
22. Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370:1483-1493.
23. Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370:1879-1888.
24. Sulkowski MS, Naggie S, Lalezari J, et al. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection. JAMA. 2014; 312:353.
25. Hu KQ, Freilich B, Brown RS, et al. Impact of Hispanic or Asian ethnicity on the treatment outcomes of chronic hepatitis C: results from the WIN-R trial. J Clin Gastroenterol. 2011;45:720-726.
26. Hays RD, Morales LS. The RAND-36 measure of health-related quality of life. Ann Med. 2001;33:350-357.
27. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002;21:271-292.
28. Younossi ZM, Guyatt G, Kiwi M, et al. Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut. 1999;45:295-300.
29. The Functional Assessment of Chronic Illness Therapy (FACIT) measurement system. Validation of version 4 of the core questionnaire. Quality of Life Research. 1999;8:604.
30. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. PharmacoEconomics. 1993;4:353-365.
31. Yu ML, Chuang WL. Treatment of chronic hepatitis C in Asia: when East meets West. J Gastroenterol Hepatol. 2009;24:336-345. doi: 10.1111/j.1440-1746.2009.05789.x.
32. World Health Organization. WHOQOL Study Protocol:The development of the World Health Organization Quality of Life assessment instrument. Geneva, Switzerland: Division of Mental Health, World Health Organization; 1993:Publication MNH/PSF/93.9.
33. Kagawa-Singer M. Bamboo and Oak: A Comparative Study of Adaptation to Cancer by Japanese-American and Anglo-American Cancer Patients [Dissertation] Los Angeles, CA: Anthropology, University of California at Los Angeles; 1988.
34. Cheng PN, Marcellin P, Bacon B, et al. Racial differences in responses to interferon-beta-1a in chronic hepatitis C unresponsive to interferon-alpha: A better response in Chinese patients. J Viral Hepat. 2004;11:418-426.
35. Chan HL, Ren H, Chow WC, et al. Randomized trial of interferon beta-1a with or without ribavirin in Asian patients with chronic hepatitis C. Hepatology. 2007;46:315-323.
36. Leng J, Lee T, Sarpel U, et al. Identifying the informational and psychosocial needs of Chinese immigrant cancer patients: A focus group study. Support Care Cancer. 2012;20:3221-3229. doi: 10.1007/s00520-012-1464-1. Epub 2012 Apr 25.
37. Ngo-Metzger Q, Sorkin DH, Mangione CM, et al. Evaluating the SF-36 Health Survey (Version 2) in Older Vietnamese Americans. J Aging Health. 2008;20:420-436. doi: 10.1177/0898264308315855. Epub 2008 Apr 1.